Royalty Report: Drugs, Disease, Therapeutic – Collection: 174194


Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 3

Primary Industries

  • Drugs
  • Disease
  • Therapeutic
  • Diabetes Treatment

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 174194

License Grant
Licensor grants an exclusive right and license, under the Licensed Patents and the Licensed Know-How, to use and sell Licensed Products in the Field throughout the Territory, and a co-exclusive license, together with Licensor for each Party to make and have made Licensed Products in the Field in the Territory.
License Property
The Licensed Product is any pharmaceutical formulation in the Field that contains any Compound as a Therapeutically Active ingredient.   Licensed Products shall include any and all Pimagedine, also known as aminoguanidine hydrochloride,  Products, Second Generation Products and Combination Products.  Pimagedine is an investigational drug for the treatment of diabetic nephropathy.

Therapeutically Active is a compound or agent has biologic activity in vivo as a therapeutic agent, and shall not include any diluent, vehicle, adjuvant or other ingredient (other than a Licensed Product) that does not have any, or has only incidental, therapeutic properties when present alone.

Field of Use
The Field is all human pharmaceutical uses of all dosage forms of all Licensed Products, and shall include, without limitation, the treatment of diabetes and the complications of diabetes.

IPSCIO Record ID: 245903

License Grant
Licensor hereby assigns to Licensee all right, title and interest in and to the Assigned Patent. On or about the Effective Date, Licensor shall execute the Assignment of Patents and Patent Applications as evidence of such assignment.  Licensor does hereby assign, sell and transfer unto Licensee, its successors and assigns, the entire, exclusive right, title and interest in and to said inventions, in any form or embodiment thereof, and in and to said applications; and in and to any and all applications filed in any country based thereon.
License Property
Assigned Patent:
U.S. Patent Application Serial Number 12/283,290
Title: 'Deuterated Pirfenidone'
Filing Date: September l 0, 2008
Publication Number: US20090131485
Publication Date: May 21, 2009

Product shall mean any pharmaceutical product containing deuterated pirfenidone.

Combination Product shall mean any pharmaceutical product which contains (a) deuterated pirfenidone and (b) at least one other ingredient which is Therapeutically Active.

Therapeutically Active shall mean that the ingredient is biologically active but shall not include diluents, vehicles, or specific adjuvants or any other ingredient which does not have any, or which has only incidental, therapeutic properties when present alone.

Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 263955

License Grant
Licensor grants an exclusive right and license in the Licensee Territory, under the Licensor Technology, for all uses in the Field, with the right to grant sublicenses, to research, develop, modify and improve Compound and Product;  apply for and obtain Regulatory Approvals; and use, import/export, market, offer to sell and sell, Product and Compound; and make, or have made, the Compound and Product for use in the Field.
License Property
The Compound means the compound identified as LU 135252 (Darusentan) and its racemates, isomers, Prodrugs, active metabolites and any pharmaceutically acceptable salt or complex thereof, in its current and any other formulation.
Field of Use
The Field means all human and non-human diagnostic, prophylactic and therapeutic uses of the Compound and/or Product in any formulation or dosage form for any and all indications except therapeutic uses and indications in the Cancer Field.

Cancer Field means the prophylactic or therapeutic administration to humans or non-human animals as an agent, either alone or in combination with other agents, for the prevention, treatment or palliation of cancer including neoadjuvant, adjuvant or supportive care and/or as part of combination with radiotherapy, surgery, chemo-, biologic- or other therapy associated with cancer, including, but not limited to, pain and bone/skeletal complications or indications from bone metastasis.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.